PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response ...
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases ...
In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s ...
Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. ...
BriaCell’s Bria-IMT ™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning ...
After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital ...
BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell’s next generation breast ...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
According to American Cancer Society Facts and Figures, breast cancer is the most common cancer ...
Accessibility Tools